NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Sees Large Decrease in Short Interest

NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) saw a significant drop in short interest in the month of January. As of January 30th, there was short interest totaling 7,529 shares, a drop of 16.5% from the January 15th total of 9,014 shares. Based on an average trading volume of 647 shares, the days-to-cover ratio is currently 11.6 days. Based on an average trading volume of 647 shares, the days-to-cover ratio is currently 11.6 days.

NeuroSense Therapeutics Stock Down 15.0%

NASDAQ NRSNW traded down $0.03 during trading on Tuesday, hitting $0.17. The company had a trading volume of 250 shares, compared to its average volume of 2,159. The company’s fifty day moving average is $0.31 and its 200-day moving average is $0.39. NeuroSense Therapeutics has a one year low of $0.15 and a one year high of $1.00.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.